BioSenic puts fracture cell therapy program on hold after mid-stage failure
BioSenic puts fracture cell therapy program on hold after mid-stage failure
BioSenic puts fracture cell therapy program on hold after mid-stage failure
Published: Jun 19, 2023
By Tristan Manalac
BioSpace
Belgium-based BioSenic is suspending the development of ALLOB, an investigational allogeneic cell therapy derived from mesenchymal stem cells, which was being assessed as a treatment for tibial fractures, the company announced Monday.
The decision to pause ALLOB’s development comes after disappointing results in a Phase IIb trial, which had been designed to evaluate the candidate’s safety and timing efficacy, according to BioSenic’s news release. Data from the study showed that early ALLOB administration failed to speed up the fracture healing process significantly.
While the cell therapy candidate missed its primary endpoint in the mid-stage trial, data still show “the excellent safety profile of ALLOB injections, with no reported serious adverse events related to experimental treatment,” Lieven Huysse, BioSenic’s chief medical officer, said in a statement.
Results from a previous Phase IIa study also showed that, when administered three-and-a-half to seven months after a fracture, ALLOB could significantly accelerate healing.
Together with its promising pre-clinical performance, these safety and efficacy data suggest that ALLOB “remains of potential benefit as an add-on to the standard of care,” according to BioSenic’s press release. This is particularly true for difficult fractures, especially of the tibia, which fails to heal in 5% to 10% of patients.
BioSenic was formed in October 2022 from the reverse merger between Bone Therapeutics, struggling with several late-stage failures and headcount reductions, and French company Medsenic. ALLOB is the former lead candidate of Bone Therapeutics.
The suspension of ALLOB’s development will allow BioSenic to focus on its most mature candidate, the investigational oral arsenic trioxide (OATO), which is in Phase III development for chronic graft versus host disease (cGVHD). Medsenic was initially developing OATO.
“The decision to halt the clinical development on difficult tibial fractures enables BioSenic to add additional resources for the development of the OATO platform and its current indications,” CEO François Rieger said in a statement.
OATO works through a primary two-pronged effect on the immune system. First, the drug induces oxidative stress on activated B and T cells, as well as other immune system cells, to promote apoptosis. OATO can also exert an immunomodulatory effect on inflammatory pathways.
Through this mechanism of action, an injectable formulation of arsenic trioxide achieved a 75% efficacy rate. BioSenic is preparing to launch its Phase III study testing an oral formulation of this drug.
Tristan Manalac is an independent science writer based in metro Manila, Philippines. He can be reached at [email protected] or [email protected].
Source: BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: